Key PointsQuestion
What is the treatment efficacy and tolerability of antidepressant combination therapy compared with monotherapy in the treatment of acute depression, and are specific combinations preferable to others?
Findings
This meta-analysis of 39 trials comprising 6751 patients found that combination treatment using a reuptake inhibitor with an antagonist of presynaptic α2-autoreceptors (mianserin, mirtazapine, trazodone) was associated with significantly superior treatment outcomes compared with monotherapy, both as first-line treatment and for nonresponder populations. The dropout numbers did not differ between treatments.
Meaning
Combination therapy using an antagonist of presynaptic α2-autoreceptors may be an effective and safe antidepressant treatment option for patients who are nonresponders to monotherapy and as a potential first-line treatment in severe cases of depression.
Importance
Combining antidepressants is frequently done in the treatment of acute depression, but studies have yielded conflicting results.
Objective
To conduct a systematic review and meta-analysis assessing efficacy and tolerability of combination therapy. Combinations using presynaptic α2-autoreceptor antagonists or bupropion were investigated separately.
Data Sources
MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials were systematically searched from each database inception through January 2020.
Study Selection
Randomized clinical trials (RCTs) comparing combinations of antidepressants with antidepressant monotherapy in adult patients with acute depression were included.
Data Extraction and Synthesis
Following guidelines from Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and recommendations from the Cochrane Handbook, 2 reviewers independently performed a literature search, study selection, data extraction, and evaluation of risk of bias. Data were pooled in random-effects analyses.
Main Outcomes and Measures
Primary outcome was efficacy measured as standardized mean difference (SMD); secondary outcomes were response, remission, change from baseline in rating scale scores, number of dropouts, and number of dropouts due to adverse events.
Results
Thirty-nine RCTs including 6751 patients were eligible. Combination treatment was statistically significantly associated with superior treatment outcomes relative to monotherapy (SMD = 0.31; 95% CI, 0.19-0.44). Combining a reuptake inhibitor with an antagonist of presynaptic α2-autoreceptors was superior to other combinations (SMD = 0.37; 95% CI, 0.19-0.55). Bupropion combinations were not superior to monotherapy (SMD = 0.10; 95% CI, −0.07 to 0.27). Numbers of dropouts and dropouts due to adverse events did not differ between treatments. Studies were heterogeneous, and there was indication of publication bias (Egger test result was positive; P = .007, df = 36), but results remained robust across prespecified secondary outcomes and sensitivity and subgroup analyses, including analyses restricted to studies with low risk of bias.
Conclusions and Relevance
In this meta-analysis of RCTs comparing combinations of antidepressants with antidepressant monotherapy, combining antidepressants was associated with superior treatment outcomes but not with more patients dropping out of treatment. Combinations using an antagonist of presynaptic α2-autoreceptors may be preferable and may be applied as a first-line treatment in severe cases of depression and for patients considered nonresponders.